Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support our pivotal Phase 3 clinical trial for a groundbreaking nanotechnology-based treatment targeting carcinoma in situ of the oral cavity (Stage 0 oral cancer). This funding is a critical milestone in our journey toward seeking regulatory approval for PRV111, our innovative treatment designed to revolutionize the standard of care for patients with rare, orphan diseases.

The continued support from the National Cancer Institute not only affirms the potential of our technology but also accelerates our ability to move forward in the regulatory process. With these resources, Privo can conduct the necessary research and clinical studies to demonstrate the safety and efficacy of our treatment, bringing us closer to delivering new therapies to patients who have limited options. This funding is instrumental in advancing our mission to make a meaningful impact on the lives of those battling rare forms of cancer, as we strive to bring this promising treatment to market.

About Privo Technologies, Inc.

Privo Technologies, Inc. (Privo) is a phase 3 clinical-stage biopharmaceutical company committed to developing innovative therapeutics designed to eliminate cancers and prevent recurrence. Privo aims to provide better and more accessible treatment options to diverse patient populations around the world with the potential to transform standard of care for treating solid tumors. Privo is headquartered in Peabody, a suburb of Boston, Massachusetts. For more information on the technology see Privo’s most recent publication (https://www.nature.com/articles/s41467-022-31859-3), described in detail in Forbes: Disruptive Innovation In Drug Delivery Systems.

Privo’s lead asset, PRV111 has been shown to be effective in patients with head and neck cancer in several hospitals across the US during a safety and efficacy Phase I/II clinical study, dramatically reducing tumor volume without any systemic toxicity. For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.

Media Contact: communicationteam@privotechnologies.com